The Effect of HBV Therapy on Glycemic Control in HBV-Infected Patients With Diabetes: A 90-day Multicenter Study

• Published in: Journal of medical virology 2025-02, Vol.97 (2), p.e70185
• Main Authors: Liu, Qi, Huang, Jie, Hu, Jingyi, Ding, Yujing, Wang, Yue, Zhang, Pan, Zhang, Zhenlan, Liu, Ying, Li, Boqi, Xiao, Biao, Cai, Ting, Yue, Tingting, Li, Xia, Reza Pourkarim, Mahmoud, De Clercq, Erik, Zhou, Zhiguang, Xiao, Yang, Li, Guangdi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antiviral Agents - therapeutic use; Blood Glucose - analysis; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Female; Glycated Hemoglobin - analysis; Glycemic Control; Hepatitis B - complications; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B virus - drug effects; Humans; Male; Middle Aged
• ISSN: 0146-6615; 1096-9071; 1096-9071
• DOI: 10.1002/jmv.70185

Patients with diabetes are at increased risk of HBV infection; however, the effects of HBV infection and anti-HBV therapy on the management of type 1 diabetes (T1D), type 2 diabetes (T2D), and latent autoimmune diabetes in adults (LADA) remain unclear. From 2016 to 2023, we recruited a multicenter cohort of 355 HBV-infected inpatients, including 136 with T1D, 140 with T2D, and 79 with LADA. The control group included 525 HBV-uninfected inpatients, comparing 171 with T1D, 204 with T2D and 150 with LADA. We employed propensity-score matching between cases and controls to minimize confounding effects. Hemoglobin A1c (HbA1c) was monitored at baseline and at months 1, 2, and 3. At baseline, median HbA1c was significantly higher in HBV-infected patients compared to their HBV-uninfected controls: T1D (10.4% vs. 7.5%, p